Bluemtec to distribute Novartis Korea's Leqvio to neighborhood clinics

Bluemtec, a pharmaceutical e-commerce company, announced on Wednesday that it has signed a domestic distribution and marketing agreement with Korean Novartis for the lipid disorder treatment Leqvio (inclisiran sodium).

Under this agreement, Bluemtech will oversee all commercial activities related to Leqvio within the nation’s clinic channel, including advertising, distribution, and sales management, and will launch a full-scale market expansion through BluePharm Korea.

Leqvio is a PCSK9-targeted siRNA agent that has rapidly expanded its market share since receiving approval from the U.S. Food and Drug Administration (FDA) in 2021. It is a long-acting treatment that reduces LDL cholesterol by more than 50 percent with only two doses per year. In the ORION-10 and 11 clinical trials, it demonstrated the ability to stably lower LDL levels for more than 18 months when used in combination with statins.

In particular, compared to existing PCSK9 inhibitors, it has a longer dosing interval and can be stored without cold chain conditions, offering advantages in terms of convenience of administration and inventory management in clinical settings. Accordingly, Bluemtech is focusing on the potential for expanding prescriptions of injectable LDL cholesterol-lowering therapies in primary care settings through Leqvio.

BluePharm Korea, which will serve as the distribution hub for Leqvio, is the largest online professional pharmaceutical platform in Korea with over 35,000 member clinics. It provides differentiated marketing solutions that go beyond simple ordering functions, including targeted advertising for medical professionals, AI-based recommendations, and digital academic content.

Notably, by adopting a strategy based on the actual clinical workflow of internal medicine and family medicine departments, which treat a high number of patients with dyslipidemia, BluePharm Korea plans to support the rapid market penetration of Leqvio.

“Leqvio not only demonstrates clinical efficacy but also features a formulation structure advantageous for use in primary care settings,” the company said. “Through BluePharm Korea, which integrates distribution and marketing centered on healthcare professionals, we aim to fundamentally transform the prescribing environment and establish new standards in clinical practice.”